ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "BLyS and Lupus"

  • Abstract Number: 2586 • 2017 ACR/ARHP Annual Meeting

    Exposure-Response Modelling and Exposure-Safety Modelling Analyses in Two Phase II Studies of Atacicept in SLE

    Orestis Papasouliotis1, Oezkan Yalkinoglu1, Cristina Vazquez-Mateo2, Stephen Wax3, Amy H. Kao2, Peter Chang3, Patricia Fleuranceau-morel2 and Lisa Mahnke2, 1Merck KGaA, Darmstadt, Germany, 2EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 3EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA

    Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL, and has been shown to reduce SLE disease activity. Our analyses evaluated the exposure-response and…
  • Abstract Number: L6 • 2012 ACR/ARHP Annual Meeting

    Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus

    Richard A. Furie1, Morton A. Scheinberg2, Gustavo Leon3, Edgar B. Ramiterre4, Matthew Thomas5, Renee S. Martin6 and Michelle Petri7, 1The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 2Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, 3Instituto De Ginecologia Y Reproduccion, Lima, Peru, 4Brokenshire Memorial Hospital, Davao City, Philippines, 5Health and Research Centre, Trivandrum, Kerala, India, 6Anthera Pharmaceuticals Inc, Hayward, CA, 7Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: To evaluate the efficacy, safety, and tolerability of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of soluble- and membrane-bound B-cell activating factor (BAFF), in patients…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.